Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioInvent International AB ( (SE:BINV) ) has provided an announcement.
BioInvent International AB has published preclinical and early Phase 1 data for BI-1607, a novel FcγRIIB-blocking monoclonal antibody, in the journal Clinical Cancer Research. The study shows promising disease control in HER2-positive advanced solid tumors, with 78% of patients experiencing stable disease. Although the BI-1607 program is currently paused, the data supports the potential of Fcγ monoclonal antibodies in enhancing cancer treatment efficacy, particularly in combination with other therapeutic antibodies like trastuzumab.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer therapy. The company is engaged in ongoing clinical programs in Phase 1/2 trials targeting cancer treatment.
Average Trading Volume: 107,786
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.98B
See more insights into BINV stock on TipRanks’ Stock Analysis page.